A mini-Genentech, focused on discovering and developing new drugs.

Like a Moderna or BioNTech, but developing oral small molecule drugs for conditions like heart failure and chronic pain.

An early-stage Vertex Pharmaceuticals, developing its own innovative drugs for specific therapeutic areas.

• Sotagliflozin: An orally-delivered small molecule drug for the treatment of heart failure and type 1 diabetes.
• LX9211: A drug currently in Phase II clinical development for the treatment of neuropathic pain.

Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of pharmaceutical products. It primarily sells its drug candidates and intellectual property through strategic collaboration and licensing agreements with other pharmaceutical companies.

Based on the provided information, its major customer companies are:

• Bristol-Myers Squibb Company (NYSE: BMY)
• Genentech, Inc. (a subsidiary of Roche Holdings AG; OTC: RHHBY)

Mike Exton, Ph.D. Chief Executive Officer and Director

Mike Exton was appointed Chief Executive Officer of Lexicon Pharmaceuticals in July 2024. He previously spent 14 years at Novartis, where his most recent roles included Cardiometabolism Therapeutic Head and Vice President and Global Head of the Cardiovascular Renal and Metabolism Franchise. Before his tenure at Novartis, Dr. Exton held various positions in research, business development, and commercial operations at Invida Pty Ltd and Eli Lilly Australia. He is recognized for leading the commercialization of a significant heart failure drug, Entresto, and developing a robust cardiometabolic business. Dr. Exton holds a B.Sc. and a Ph.D. in neuroscience from the University of Newcastle, and a Ph.D. in immunology from the University of Essen, Germany.

Scott Coiante Senior Vice President and Chief Financial Officer

Scott Coiante was appointed Senior Vice President and Chief Financial Officer of Lexicon Pharmaceuticals, effective January 2, 2025. He brings over 35 years of experience in finance within the life science and pharmaceutical industries. Prior to joining Lexicon, Mr. Coiante served as Senior Vice President, Chief Financial Officer, and Treasurer of Agile Therapeutics Inc. across two separate tenures, from 2011 to 2019 and from August 2023 to August 2024. He also held the roles of Senior Vice President, Chief Financial Officer, Treasurer, and Secretary at Aprea Therapeutics. Earlier in his career, he held several senior financial positions at Medarex Inc., where he facilitated the company's transition following its acquisition by Bristol-Myers Squibb. Mr. Coiante earned a B.S. in Accounting from Villanova University.

Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer

Brian P. Zambrowicz is a co-founder of Lexicon Pharmaceuticals Inc. He has served as Executive Vice President and Chief Scientific Officer since 2007. Dr. Zambrowicz has been crucial in establishing the company's scientific direction, including the development of its proprietary gene knockout technology and small molecule drug discovery pipeline. His responsibilities include overseeing scientific operations from target discovery to the selection of clinical candidates for both small molecule and antibody therapeutics. He also managed Lexicon's strategic alliances, including those with Bristol-Myers Squibb Company and Genentech, Inc. Before joining Lexicon, Dr. Zambrowicz was an NIH postdoctoral fellow at The Fred Hutchinson Cancer Center. He earned his B.S. in biochemistry from the University of Wisconsin, Madison, and his Ph.D. in biochemistry from the University of Washington, Seattle.

Alan J. Main, Ph.D. Executive Vice President, Commercial Supply Operations

Alan J. Main joined Lexicon Pharmaceuticals in July 2001 as part of the company's acquisition of Coelacanth Corporation. Prior to the acquisition, he served as President and Chief Executive Officer of Coelacanth Corporation, which specialized in proprietary chemistry technologies for drug development. Earlier in his career, Dr. Main spent 20 years at Novartis Pharmaceuticals Corporation as Senior Vice President, U.S. Research. He holds a B.S. from the University of Aberdeen, Scotland, a Ph.D. in organic chemistry from the University of Liverpool, England, and completed postdoctoral studies at the Woodward Research Institute.

Craig Granowitz, MD, PhD Senior Vice President and Chief Medical Officer

Craig Granowitz joined Lexicon as Senior Vice President and Chief Medical Officer, effective August 2, 2021. Before his role at Lexicon, he served as Chief Medical Officer at Amarin Corporation plc. Prior to Amarin, Dr. Granowitz was Senior Vice President and Head of Global Medical Affairs, Global Human Health at Merck & Co., Inc., where he was responsible for establishing a new global medical affairs organization following the merger with Schering-Plough Corporation. At Schering-Plough, he held various medical and commercial management positions, including Group Vice President, Head of Global Medical Affairs, and Senior Vice President of a $2.5 Billion Virology Business Unit. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.

The key risks for Lexicon Pharmaceuticals (LXRX) primarily revolve around the inherent challenges of the biopharmaceutical industry, particularly concerning regulatory hurdles, clinical trial outcomes, and financial stability.

1. Regulatory Challenges and Pipeline Dependence: Lexicon Pharmaceuticals faces significant regulatory risks, notably demonstrated by the FDA's repeated rejection of sotagliflozin (Zynquista) for type 1 diabetes due to safety concerns, specifically the risk of diabetic ketoacidosis. While sotagliflozin was approved for heart failure (as Inpefa), the company's future remains highly dependent on the successful clinical development and regulatory approval of its other pipeline candidates, such as LX9211 for neuropathic pain. Clinical trial failures or significant delays for these key assets could severely impact the business, and the company may also require partnerships to fund expensive late-stage trials.
2. Financial Stability and Cash Runway: As a biopharmaceutical company primarily focused on development, Lexicon Pharmaceuticals currently operates at a loss with negative operating and net margins. The company's financial health is a critical risk factor, with concerns about its cash burn rate and cash runway. While cost reductions and licensing revenues have been implemented, Lexicon faces the ongoing challenge of managing high research and development (R&D) costs and lengthy development cycles, which could necessitate future capital raises and potentially dilute shareholder value.
3. Intense Competition: The pharmaceutical sector is highly competitive, especially in therapeutic areas such as cardiometabolic diseases and diabetes, which are central to Lexicon's product portfolio. This intense competition from other pharmaceutical companies, including larger players with greater resources, poses a risk to Lexicon's ability to innovate, achieve market penetration, and maintain favorable market positioning for its approved and pipeline products.

Lexicon Pharmaceuticals, Inc. (LXRX) is focused on developing and commercializing pharmaceutical products for various conditions. The addressable markets for their main product candidates are detailed below:

• Sotagliflozin (INPEFA) for Heart Failure:

  The global heart failure market was valued at over $20 billion in 2023 and is projected to reach approximately $40 billion by 2032. More specifically, the chronic heart failure market size in the 7 Major Markets (7MM), which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was around USD 8 billion in 2023. The U.S. chronic heart failure market alone was approximately USD 5.5 billion in 2023. The advanced heart failure market within the 7MM reached USD 6.50 billion in 2024 and is expected to grow to USD 27.60 billion by 2035. In the United States, the prevalence of heart failure was 6.7 million patients in 2019, with an estimation to reach eight million by 2030. The market for Sotagliflozin specifically (INPEFA) generated a revenue of USD 80.0 million globally in 2024 and is expected to reach USD 108.0 million by 2033. Another report estimates the Sotagliflozin market size at USD 315.75 million in 2024, projected to reach USD 720.40 million by 2032 globally.

• Sotagliflozin (Zynquista) for Type 1 Diabetes:

  The global Type 1 Diabetes market size was estimated at USD 16.01 billion in 2024 and is projected to reach USD 31.48 billion by 2035. Another estimate places the global market at USD 16.97 billion in 2025, expecting it to reach USD 26.22 billion by 2032. The global market size is also reported as USD 37.60 billion in 2025, predicted to increase to approximately USD 79.14 billion by 2035. North America is a dominant region in the global Type 1 Diabetes market, holding an estimated 39.4% market share in 2025 and is expected to lead the global market through 2035. The United States specifically accounts for approximately 89% of the Type 1 Diabetes market share within the 7 Major Markets.

• LX9211 for Neuropathic Pain:

  The global neuropathic pain market was valued at USD 7.7 billion in 2022 and is projected to reach USD 13.3 billion by 2032. Other estimates show the global neuropathic pain market size at USD 5.5 billion in 2023, expected to reach USD 8.1 billion by 2034, or USD 8.59 billion in 2025, increasing to approximately USD 16.79 billion by 2034. Another report states the neuropathic pain market was valued at USD 2.83 billion in 2024 and is poised to grow to USD 4.51 billion by 2033. For diabetic neuropathic pain (DNP), a segment of neuropathic pain, the market across the 7 Major Markets (US, 5EU, and Japan) is expected to grow from USD 1.7 billion in 2021 to USD 3.0 billion in 2031. The global diabetic neuropathy treatment market was estimated at USD 4.34 billion in 2023 and is projected to reach USD 7.28 billion by 2030. In the U.S., approximately 35 million cases of peripheral neuropathic pain were recorded in 2023. The U.S. was the largest market for DNP treatments in 2021, representing 51.4% of global sales, and is expected to continue dominating, reaching USD 2.2 billion by 2031.

Lexicon Pharmaceuticals (LXRX) is expected to experience future revenue growth over the next 2-3 years driven by several key factors:

1. Commercialization of Zynquista (sotagliflozin) for Type 1 Diabetes: Lexicon Pharmaceuticals plans to resubmit its New Drug Application (NDA) for Zynquista as an adjunct to insulin in adults with type 1 diabetes in 2026. This resubmission could lead to potential regulatory approval and a subsequent launch, establishing a new significant revenue stream for the company.
2. Advancement of Sotagliflozin in Hypertrophic Cardiomyopathy (HCM): The SONATA-HCM Phase 3 clinical trial, evaluating sotagliflozin for the treatment of hypertrophic cardiomyopathy, is on track to complete enrollment by mid-2026, with top-line results anticipated in the first quarter of 2027. Positive outcomes from this pivotal trial would pave the way for a potential new indication and market expansion for sotagliflozin.
3. Progress and Potential Partnership for LX9211 (pilavapadin) in Diabetic Peripheral Neuropathic Pain (DPNP): Lexicon is advancing LX9211 into late-stage development for diabetic peripheral neuropathic pain. Following positive top-line data from the Phase 2b PROGRESS study (anticipated Q1 2025), successful progression to Phase 3, potentially with a development partner, would bring this candidate closer to commercialization and contribute to future revenue growth.
4. Milestone Payments and Future Royalties from LX9851 Collaboration with Novo Nordisk: Lexicon has an exclusive licensing agreement with Novo Nordisk for LX9851 in obesity and related disorders. The company received a $10 million milestone payment in February 2026 and has the potential to earn up to an additional $20 million in milestones in 2026, along with tiered royalties on net sales of LX9851. These payments will contribute to Lexicon's revenue.
5. Growth in INPEFA (sotagliflozin) Sales for Heart Failure: INPEFA, an orally-delivered small molecule drug, is already commercialized for heart failure. Continued efforts in its commercialization and market penetration are expected to drive growth in net product sales, contributing to Lexicon's overall revenue.

Share Issuance

• In January 2026, Lexicon Pharmaceuticals successfully priced a public offering of 32 million shares at $1.30 each, raising $41.6 million.
• Concurrently in January 2026, the company arranged a private placement with Invus, L.P., its largest shareholder, which is expected to generate an additional $41.1 million through the sale of common shares and Series B convertible preferred stock.
• In March 2024, Lexicon completed a private investment in public equity (PIPE) financing, raising approximately $250 million through the sale of Series A convertible preferred stock to a group of accredited investors, including an affiliate of Invus, L.P.

Inbound Investments

• In March 2025, Lexicon entered into an exclusive licensing agreement with Novo Nordisk for LX9851, an obesity drug candidate, which included a $45 million upfront payment received in April 2025.
• A $10 million milestone payment from Novo Nordisk for LX9851 was triggered in January 2026.
• The company received a $25 million upfront payment in 2024 from Viatris for sotagliflozin licensing.

Capital Expenditures

• Lexicon Pharmaceuticals' capital expenditures were $1.0 million in 2025.
• Research and development (R&D) expenses were $61.1 million in 2025, a decrease from $84.5 million in 2024.
• Expected R&D expenses for 2026 are projected to be between $63 million and $68 million, primarily focused on the continued research, development, and commercialization of drug candidates such as sotagliflozin and LX9851.